ABBV
AbbVie Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$282.79
−0.92%Year over year
Reported trailing growth
- Revenue
- +10.4%
- EBITDA
- +49.6%
- EBIT
- +72.1%
- EPS
- +68.1%
- Free cash flow
- -0.2%
- Operating cash flow
- +1.2%
Forward estimates
Based on analyst estimates
- Revenue
- +10.8%
- EBITDA
- +100.6%
- EPS
- +340.8%
Three-year CAGR
- Revenue
- +1.8%
- EBITDA
- -10.0%
- EBIT
- +3.5%
- Net income
- -29.1%
- EPS
- -29.1%
- Free cash flow
- -9.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026